Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olaparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 20/20 | 1.00 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 1/20 | 1.00 |
| ▸ | PARP3 known ✓ | Q9Y6F1 | 1/20 | 1.00 |
| ▸ | TNKS | O95271 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 1.00 |
| ▸ | PARP15 | Q460N3 | 1/20 | 1.00 |
| ▸ | PARP14 | Q460N5 | 1/20 | 1.00 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 1.00 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 1.00 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 1.00 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 1.00 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 1.00 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 1.00 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olaparib SCHEMBL426568 | 1.00 | PARP1 (1.00) | PARP1TNKSADORA1CDK6PDE3A | |
| Olaparib SCHEMBL29392087 | 1.00 | PARP1 (1.00) | PARP1TNKSADORA1CDK6PDE3A | |
| Olaparib SCHEMBL28083947 | 0.96 | PARP1 (0.93) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL22852727 | 0.96 | PARP1 (0.98) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL28732627 | 0.95 | PARP1 (0.91) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL22829780 | 0.94 | PARP1 (1.00) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL19569971 | 0.92 | PARP1 (0.90) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL22852988 | 0.91 | PARP1 (0.89) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL9280839 | 0.91 | PARP1 (0.83) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL15846235 | 0.91 | PARP1 (0.83) | PARP1TNKSADORA1CDK6PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14359 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4048809-B1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4071174-B1 | METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB | ASTRAZENECA AB (SE) | 2026-05-27 | — | — | EP | claimed |
| CN-122094673-A | Anti-PD-L1 antibodies for use in combination with one or more chemotherapeutic agents for the treatment of endometrial cancer | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| CN-116162546-B | Drug screening tumor organoid chip and drug screening method | DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2026-05-26 | — | — | CN | claimed |
| US-12637510-B2 | Oncolytic virus compositions and methods for the treatment of cancer | CITY OF HOPE (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026106998-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR AND RELATED COMPOSITION AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260137700-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2026-05-21 | — | — | US | claimed |
| WO-2026106315-A1 | METHOD FOR PROVIDING INFORMATION ON ATM GENE FUNCTION | 연세대학교 산학협력단 | 2026-05-21 | — | — | WO | claimed |
| WO-2026104998-A1 | SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2026-05-21 | — | — | WO | claimed |
| WO-2022023381-A1 | METHODS FOR IDENTIFYING CHROMOSOMAL SPATIAL INSTABILITY SUCH AS HOMOLOGOUS REPAIR DEFICIENCY IN LOW COVERAGE NEXT-GENERATION SEQUENCING DATA | SOPHIA GENETICS S.A. (CH) | 2022-02-03 | — | — | WO | claimed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | claimed |
| EP-3080292-B1 | METHODS FOR DETECTING INACTIVATION OF THE HOMOLOGOUS RECOMBINATION PATHWAY (BRCA1/2) IN HUMAN TUMORS | INST CURIE (FR) | 2022-02-02 | — | — | EP | claimed |
| CN-113440533-B | Application of stachyose in preparing medicine for treating castration resistant prostate cancer | 江南大学 | 2022-02-01 | — | — | CN | claimed |
| US-20220025053-A1 | Methods of Inhibiting Metastasis in Cancer | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2022-01-27 | — | — | US | claimed |
| US-20220028481-A1 | METHODS FOR IDENTIFYING CHROMOSOMAL SPATIAL INSTABILITY SUCH AS HOMOLOGOUS REPAIR DEFICIENCY IN LOW COVERAGE NEXT-GENERATION SEQUENCING DATA | SOPHIA GENETICS S.A. (CH) | 2022-01-27 | — | — | US | claimed |
| US-20220025468-A1 | HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY DETECTION | GUARDANT HEALTH, INC. | 2022-01-27 | — | — | US | claimed |
| US-20220023405-A1 | USE OF LEUKEMIA-DERIVED CELLS IN OVARIAN CANCER VACCINES | Mendus B.V. (NL) | 2022-01-27 | — | — | US | claimed |
| WO-2022020218-A1 | DIAGNOSTIC METHODS FOR CANCER USING AXL DECOY RECEPTORS | ARAVIVE INC (US) | 2022-01-27 | — | — | WO | claimed |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | SENHWA BIOSCIENCES, INC. (TW) | 2022-01-25 | — | — | US | claimed |